The collaboration includes a phase 1 clinical study to start in the second quarter of 2025.

The National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) have signed a memorandum of understanding (MoU) to advance research in acne treatment.

The collaboration includes a phase 1 clinical study involving patients with mild acne, expected to commence in the second quarter of 2025.

In addition, a translational study will be conducted to explore key biological markers that impact acne severity.

The chronic inflammatory skin condition affects a significant portion of the population, with approximately 80% of teenagers and an increasing number of adults—an estimated 40%—experiencing the condition.